Head of the Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg/Essen and Professor, University of Duisburg/Essen, Essen, Germany.
Resident Physician at the Department of Internal Medicine, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg/Essen, Castrop-Rauxel, Germany.
J Psychoactive Drugs. 2023 Jan-Mar;55(1):102-111. doi: 10.1080/02791072.2022.2050858. Epub 2022 Mar 15.
To shed more light on the addictive power of the gabapentinoids (GPTs) gabapentin and pregabalin, we performed a structured face-to-face interview with GPT-users about DSM-IV-dependence-criteria (sedatives), consume-motives and cessation-needs. Among 100 patients consecutively admitted to a detoxification-ward, fifteen (15%) reported lifetime GPT-use (18-50 years old, 2 females): seven (7%) used gabapentin, twelve (12%) pregabalin and four had lifetime experiences with both GPTs. Of the seven gabapentin-users, three patients were dependent including one person with a spontaneous remission. Of the 12 pregabalin-users, five were dependent, including two persons with a spontaneous remission. Fourteen of fifteen cases reported GPT-use side-by-side with an opioid-use, mostly for sparing opioids. Twelve GPT-users additionally co-used benzodiazepines. In no case, a GPT was the reason for detoxification treatment or reported to be involved in an emergency event. Altogether, every 7 patient (n = 15) of our inpatient detoxification-seeking sample reported GPT-use including 50% (n = 8) who were dependent. Among them, 35% (3/8) had been already spontaneously remitted. As GPT-users reported no cession-need and the vast majority were primarily affected by co-occurring opioid- and benzodiazepine-addiction, we assume that GPTs more likely played a bystander-role than mediating the addictive behavior of this population with multiple recreational drug use experience.
为了更深入地了解加巴喷丁类药物（GPTs）加巴喷丁和普瑞巴林的成瘾性，我们对 GPT 用户进行了一次结构式面对面访谈，探讨了 DSM-IV 依赖标准（镇静剂）、使用动机和戒断需求。在连续收治到戒毒病房的 100 名患者中，有 15 名（18-50 岁，2 名女性）报告称有过 GPT 使用史（15%）：7 名（7%）使用过加巴喷丁，12 名（12%）使用过普瑞巴林，还有 4 名患者有过两种 GPT 的使用经历。在 7 名使用加巴喷丁的患者中，有 3 名患者依赖药物，其中包括 1 名患者出现了自发缓解。在 12 名使用普瑞巴林的患者中，有 5 名患者依赖药物，其中包括 2 名患者出现了自发缓解。在 15 名患者中，有 14 名报告称同时使用 GPT 和阿片类药物，主要是为了减少阿片类药物的使用。12 名 GPT 用户还同时使用了苯二氮䓬类药物。在任何情况下，都没有 GPT 是导致戒毒治疗的原因，也没有报告称 GPT 与紧急事件有关。总的来说，我们住院戒毒的样本中，每 7 名患者（n=15）就有 1 名报告有 GPT 使用史，其中 50%（n=8）患者依赖 GPT。其中，35%（3/8）已经自发缓解。由于 GPT 用户没有戒断需求，且绝大多数患者主要受到阿片类药物和苯二氮䓬类药物共病成瘾的影响，我们认为 GPT 更可能扮演旁观者角色，而不是介导这群有多种娱乐性药物使用经历的人的成瘾行为。
